The Tamesis
The market valuation in 2024 is US$110 million.
According to a DelveInsight report, the macrophage activation syndrome segment in the six major markets (6MM) is expected to expand at a CAGR of 24.7% by 2034.
The industry’s expansion is attributed to expanded treatment options, improved survival outcomes, and the introduction of emerging therapies.
The market is valued at $110 million in 2024, with the United States accounting for 91% of the market during that period.
Current treatments include glucocorticoids, cytokine-targeted biologics, and GAMIFANT (emapalumab). Meanwhile, major industry players are developing new treatments that are expected to enter the market in the coming years, the report said.
In 2024, 6MM reported approximately 22,000 confirmed cases, a number that is expected to increase over the forecast period due to autoimmunity, autoinflammation, and infectious diseases.
MAS affects children and adults and is commonly associated with systemic juvenile idiopathic arthritis and Still’s disease in adults.
6MM = USA, Germany, France, Italy, Spain and UK.
